Gajarski R J, Kearney D L, Price J K, Denfield S W
Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Tex Heart Inst J. 1997;24(4):260-8.
Despite evolution to "higher-order" immunosuppressive agents that better control cell-mediated allograft rejection and, therefore, short- and intermediate-term survival, allograft vasculopathy and PTLD remain factors that limit extended graft survival. While improved basic science "bench" techniques have enabled investigation of their pathogenesis at the subcellular and molecular levels, each scientific advance leads the way to the next horizon of complex questions. Only through a more complete understanding of the etiology and pathophysiology of these processes will we be able to design strategies to combat these complications.
尽管已发展出“高阶”免疫抑制剂，能更好地控制细胞介导的同种异体移植排斥反应，从而提高短期和中期生存率，但同种异体移植血管病变和移植后淋巴组织增生性疾病仍是限制移植长期存活的因素。虽然改进的基础科学“实验室”技术使人们能够在亚细胞和分子水平研究它们的发病机制，但每一项科学进展都会引出下一个复杂问题的新领域。只有更全面地了解这些过程的病因和病理生理学，我们才能设计出应对这些并发症的策略。
